Torquay

This is a multicenter, open-label, randomized Phase 2a study to evaluate the safety and efficacy of 83-0060 (Ratutrelvir) and Nirmatrelvir-Ritonavir (Paxlovid) in non-hospitalized symptomatic adult participants with mild to moderate COVID-19.

Researchers are evaluating BHV-1300 as a potential treatment for people diagnosed with Graves' Disease. This Phase 1 open-label study aims to assess the safety of BHV-1300 and investigate its effects on biomarkers related specifically to this disease. Participants will receive BHV-1300 through subcutaneous injections. The study does not mention multiple groups or comparator treatments, focusing solely on monitoring participants treated with BHV-1300. During the 52-week study period, researchers will monitor participants for serious adverse events, side effects leading to discontinuation, and any deaths. They will also assess laboratory test abnormalities related to treatment over the same time frame to ensure safety and gather important health data.